Yongxin Zhang,


Virology and immunology

Beijing Medical University





Yongxin Zhang, CEO and president of Zyxell Inc., graduated from Beijing Medical University (Beijing, China) for his MD in 1983 and Ph.D. in 1989, and completed his postdoctoral training in Baylor College of Medicine (Houston, USA) in 2004 for molecular virology and immunology. In these periods, his studies include transplantation immunology, pathogeneses of viral hepatitis, HIV vaccine and immunoassays.  He worked as a physician in china for more than 10 years before he came to US and he worked for Methrogen Inc., Regenetech Inc, and several other companies as a senior scientist or director of research for over 10 years after he came to US. His research areas include Immunology, Microbiology, cell transplantation, stem cell technology and bioreactor development.  His studies in past 10 years have been more focused on cancer immunology and cancer immunotherapy.

Area of Interests

  • Blockage of CTLs and NK cells-induced
  • Reduction of HSC immune rejection by Crispr/Cas9 modified HLA Gene expression
  • Cancer stem cells-related cancer immune evasion
  • Reversal of immunosenescence